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Abstract
Background: Increased rates of autoinflammatory and autoimmune disorders have been observed in female premutation
carriers of CGG repeat expansion alleles of between 55–200 repeats in the fragile X mental retardation 1 (FMR1) gene. To
determine whether an abnormal immune profile was present at a cellular level that may predispose female carriers to
autoinflammatory conditions, we investigated dynamic cytokine production following stimulation of blood cells. In
addition, splenocyte responses were examined in an FMR1 CGG knock-in mouse model of the fragile X premutation.
Methods: Human monocyte and peripheral blood leukocytes (PBLs) were isolated from the blood of 36 female FMR1
premutation carriers and 15 age-matched controls. Cells were cultured with media alone, LPS or PHA. In the animal model,
splenocytes were isolated from 32 CGG knock-in mice and 32 wild type littermates. Splenocytes were cultured with media
alone or LPS or PMA/Ionomycin. Concentrations of cytokines (GM-CSF, IL-1b, IL-6, IL-10, IL-13, IL-17, IFNc, TNFa, and MCP-1)
were determined from the supernatants of cellular cultures via Luminex multiplex assay. Additionally, phenotypic cellular
markers were assessed on cells isolated from human subjects via flow cytometry.
Results: We found decreases in cytokine production in human premutation carriers as well as in the FMR1 knock-in mice
when compared with controls. Levels of cytokines were found to be associated with CGG repeat length in both human and
mouse. Furthermore, T cells from human premutation carriers showed decreases in cell surface markers of activation when
compared with controls.
Conclusions: In this study, FMR1 CGG repeat expansions are associated with decreased immune responses and immune
dysregulation in both humans and mice. Deficits in immune responses in female premutation carriers may lead to increased
susceptibility to autoimmunity and further research is warranted to determine the link between FMR1 CGG repeat lengths
and onset of autoinflammatory conditions.
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Introduction
The fragile X mental retardation 1 (FMR1) gene, encoding for
the FMR1 protein (FMRP), contains a trinucleotide (CGG) repeat
element in the 59 untranslated region of FMR1. The length of the
CGG repeat in most individuals is less than 55 repeats. However,
carriers of a full mutation have CGG repeat expansions greater
than 200, resulting in methylation and silencing of the gene, an
absence of FMRP, and the subsequent development of fragile X
syndrome (FXS). In between are premutation carriers who have
between 55–200 CGG repeats on FMR1, increased FMR1 mRNA
expression levels, slightly reduced levels of FMRP, and are at risk
for developing a number of neurological and physiological
symptoms [1]. The prevalence of premutation alleles in the
general population is surprisingly high, with rates in men
estimated to be as 1 in 250 and in women as high as 1 in 130 [2].
The cause of the premutation phenotypes have been attributed
to elevated levels of FMR1 mRNA leading to sequestration of
proteins including Drosha and DGCR8, critical for processing of
miRNAs [3]. For example, sequestration of Drosha and DGCR8
in brain tissue from premutation carriers is associated with
decreased miRNA levels in FXTAS [3]. A recent report provides
evidence for an additional mechanism of toxicity resulting from
non-AUG-initiated (RAN) translation of CGG repeat expansions
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leading to production of a toxic polyglycine peptide [4]. There is
also evidence that psychiatric problems including anxiety and
ADHD may be relate to lower FMRP levels, particularly those
with a higher CGG repeat [5].
A number of phenotypes are associated with the expanded
CGG allele. One of the earliest associated disorders observed in
premutation carriers was primary ovarian insufficiency (FXPOI),
noted in approximately 16–20% of female carriers [6–9]. Fragile
X-associated tremor/ataxia syndrome (FXTAS) was described
later in premutation carriers who developed intention tremor and
gait ataxia [10,11]. FXTAS occurs in approximately 40% of male
permutation carriers and in 8% of female premutation carriers
over the age of 50 [12]. Additional symptomology has since been
observed, including, depression and anxiety [13,14] and hyper-
tension [15,16]. Moreover, significantly increased rates of immune
mediated disorders are observed in female permutation carriers
but have not been observed in male permutation carriers [15,17].
Little is known about the immune function of premutation
carriers. Previous reports on immune function in female premuta-
tion carriers have shown significantly increased rates of autoim-
mune and autoinflammatory disorders, such as autoimmune
thyroid disorders and fibromyalgia [17]. These increased rates
were not observed in male carriers, but this may related to the
relative rarity of these disorder in males. While not presenting with
increased development of similar immune related disorders as
female carriers, male carries are more prone to develop other
symptomology such as FXTAS. In males with FXTAS, inflam-
matory profiles, similar to those seen in autoimmune and
autoinflammatory disorders, have been observed suggesting that
immune dysregulation exists in males as well [18]. However, it is
not clear what the immune profile of premutation carriers looks
like before the appearance of immune related disorders and
whether this profile belies a susceptibility to autoimmune and
autoinflammatory disorders.
In this current study we sought to determine whether cytokine
production in healthy human female premutation carriers without
evidence for preexisting immune disorders or FXTAS was altered
at the cellular level. In addition, we investigated whether parallel
immune findings were present in a mouse model of the fragile X
premutation [19]. We hypothesize that carriers of premutation
alleles will display immune profiles of dysregulation in dynamic
cytokine production and altered cellular activation phenotypes.
Methods
Ethics Statement
The human subject portion of this study was approved by the
institutional review board (IRB) at UC Davis Medical Center. All
patients provided written informed consent. All experiments mice
were conducted under a research protocol approved by the
Institutional Care and Use Committee (IACUC) at the University
of California Davis.
Subjects
Blood samples were obtained from 36 female premutation
carriers age 19–72 years [median 45.1 years (interquartile range
36.0–53.3)] who were recruited through the Fragile X Treatment
and Research Center at the MIND Institute at University of
California, Davis, and who participated in our genotype–
phenotype study of families with fragile X between the years
2000 and 2011. Blood samples were also obtained from 15 female
controls age 18–87 years [44.8 years (27.6–62.8 years)]. Subjects
were excluded from the study if they had preexisting immune
conditions, FXTAS, or were on immune modulating medications
(methotrexate and prednisone). FXTAS was excluded utilizing
criteria reported by Jacquemont et al. [20].
Animals
Spleens were obtained from thirty-two CGG KI mice (16 males
and 16 females) and thirty-two wildtype (WT) littermate mice (16
males and 16 females) used for immune studies. Mice were bred at
UC Davis and were congenic on a C57BL/6J background. CGG
KI mice were generated by backcrossing mice initially on a mixed
FVB/N6C57BL/6J onto a C57BL/6J background over .12
generations [21]. All mice were 6 months of age at the time of
experimentation to examine older adult (but not aged) immune
profiles in the model. Mice were maintained by the Center for
Laboratory Animal Research, at University of California, Davis
and maintained at ambient room temperature on a 12 hour light/
dark cycle (light on at 06:00). Food and water were provided ad
libitum.
Genotyping
CGG repeat number in female premutation carriers and age
matched controls were measured from dried blood spots using
Southern Blot and PCR analysis as previously described [22,23].
Genotyping of mice to verify CGG repeat length was carried out
upon tail snips taken both at birth, and then again when animals
were sacrificed. DNA was extracted from mouse-tail snips as
previously described [24]. The number of CGG repeats were
determined by PCR using the Expanded High Fidelity Plus PCR
System (Roche Diagnostics, Indianapolis, IN, USA) using forward
and reverse primers previously reported [24]. The DNA bands
were separated using agarose gels and stained with ethidium
bromide to identify their sizes.
Cellular Isolation
Human whole blood was collected in acid-citrate-dextrose
Vacutainer tubes (BD Biosciences) and upon arrival, samples are
centrifuged for 2300 rpm, the plasma removed and banked at 2
80uC. Cells were be re-suspended in Hank’s Balanced Salt
Solution, layered over 15 ml of Histopaque centrifuged at
1700 rpm for 30 minutes and peripheral blood mononuclear cells
(PBMC) harvested. Isolated PBMC were resuspended in magnetic
separation buffer (Miltenyi, Auburn, CA) and monocytes were
isolated using CD14 microbeads (Miltenyi). The CD14 depleted
cells were termed peripheral blood leukocytes (PBL) and contained
mostly lymphocytes.
Monocyte and PBL Stimulation
Monocytes and PBL’s were adjusted to a concentration of
16106 cells/ml with RPMI 1640 (Invitrogen, Carlsbad, CA)
media supplemented with 10% low endotoxin, heat inactivated
fetal bovine serum (Invitrogen), 100 IU/mL penicillin, and
100 IU/ml streptomycin. Monocytes were cultures in 96 well
plates (200 mL) and PBLs in 12-well plates (1.0 mL). Monocytes
received either media alone or lipopolysaccharide (LPS; 50 mg/
mL). PBLs received media alone or PHA (20 mg/mL). Cells were
incubated at 37uC, 5% CO2/95% air. After 24 hours, cell culture
supernatants were collected and stored at 280uC until cytokine
analysis.
Murine Cell Stimulation
Mice were sacrificed and spleens collected for tissue processing.
Briefly, spleens were pressed through a 100 mM nylon filter to
obtain cells into suspension. Cells were then pelleted following
centrifugation and red blood cells were lysed using ammonium-
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chloride-potassium (ACK) lysis buffer. Cells (56106/mL) were
stimulated for 24 hours in a complete RPMI 1640 (Invitrogen)
media supplemented with 10% low endotoxin, heat inactivated
fetal bovine serum (Invitrogen), 100 IU/ml penicillin, and
100 IU/ml streptomycin (Sigma, St Louis, MO), 25 mg/ml
gentimycin (Sigma), 50 mM 2-mecaptoethanol (Sigma) with media
alone, LPS (1 mg/mL) or phorbol 12-myristate 13-acetate (PMA)/
Ionomycin (100 ng/mL/100 uM). After 24 hours, supernatants
were collect and stored at 280uC.
Cytokine Analysis
Quantification of GM-CSF, IL-1b, IL-6, IL-10, IL-12(p40), IL-
13, IL-17, IFNc, TNFa, and MCP-1 in supernatants was carried
out using murine or human multiplexing bead immunoassays
(Millipore, Billerica, MA). Additionally, IL-1a was analyzed in
human multiplex kits. Samples were run per manufacturer
specifications. Specifically, 25 mL of supernatant was incubated
with antibody-coupled beads. After a series of washes, a
biotinylated detection antibody was added to the beads, and the
reaction mixture was detected by the addition of streptavidin–
phycoerythrin. The bead sets were analyzed using a flow-based
Luminex 100 suspension array system (Bio-Plex 200; Bio-Rad
Laboratories, Inc.). Unknown sample cytokine concentrations
were calculated by Bio-Plex Manager software using a standard
curve derived from the known reference cytokine concentrations
supplied by the manufacturer. A five-parameter model was used to
calculate final concentrations and values are expressed in pg/ml.
The sensitivity of this assay allowed the detection of cytokine
concentrations with the following limits of detection: (Human)
GM-CSF (9.5 pg/mL), IL-1a (1.5 pg/mL), IL-1b (0.7 pg/mL),
IL-6 (0.4 pg/mL), IL-10 (0.3 pg/mL), IL-12(p40)(10.5 pg/mL),
IL-13 (0.3 pg/mL), IL-17 (0.4 pg/mL), IFNc (0.4 pg/mL), TNFa
(0.2 pg/mL), MCP-1 (1.2 pg/mL). (Murine) GM-CSF (9.5 pg/
mL), IL-1b (2.7 pg/mL), IL-6 (3.4 pg/mL), IL-10 (8.0 pg/mL),
IL-12(p40)(4.9 pg/mL), IL-13(10.8 pg/mL), IL-17 (0.8 pg/mL),
IFNc (2.3 pg/mL), TNFa (1.4 pg/mL), MCP-1 (9.1 pg/mL).
Supernatant aliquots were free of any previous freeze/thaw cycle.
Flow Cytometry
Following 24 hour culture with media alone or with anti-CD3
(0.5 mg/mL)/anti-CD28 (1 ml/mL) antibodies, cells were labeled
with antibodies specific for cell surface markers CD3+, CD25+ and
HLA-DR+ or isotype controls using methods previously utilized by
our group [25–27]. In brief, cells were incubated with antibodies
for 20 minutes on ice, then washed and fixed in 1% paraformal-
dehyde (Sigma). Multi-color flow cytometry was performed using
an LSR II (BD Bioscience) equipped with a solid state Coherent
Sapphire blue laser (20 mW @ 488 nm), Coherent VioFlame
PLUS violet laser (25 mW @ 405 nm), and a HeNe laser (18 mW
@ 633 nm). Data acquired by flow cytometry was analyzed using
FlowJo Version 10 (TreeStar; Ashland, OR).
Statistical Analysis
Data analysis was performed using STATA 12 software.
Wilcoxan rank-sum tests were used to compare cytokine levels
between subject groups. Spearman correlations were used to
determine the association between cytokine levels and CGG
repeat length. A probability value (p) of less than 0.05 was
considered to be significant.
Results
Unstimulated monocytes (Figure 1 A–C) from adult human
female premutation carriers showed significantly decreased
cytokine production compared with age-matched controls for
GM-CSF [median 8.9 pg/mL (interquartile range 1.7–15.3 pg/
mL) vs. 41.3 pg/mL (9.0–72.8 pg/mL); p= 0.015], and for IL-
12(p40) [7.8 pg/mL (2.8–20.7 pg/mL) vs. 22.6 pg/mL (16.4–
56.1 pg/mL); p = 0.042] (Figure 1 A–C). After stimulation with
LPS (Figure 1 D–F) GM-CSF, however, no longer displayed
statistically significant differences between premutation carriers
and controls after LPS stimulation. However, both IL-12(p40)
[10.3 pg/mL (3.2–20.2 pg/mL) vs. 32.9 pg/mL (20.5–50.4 pg/
mL); p = 0.029] and IL-1a [588.3.6 pg/mL (387.4–770.4 pg/mL)
vs. 846.3 (607.6–1045.3 pg/mL); p= 0.040] were significantly
decreased in premutation carriers.
Similar to the monocytes, unstimulated PBLs (Figure 2 A–D)
from adult human female premutation carriers also showed
decreased cytokine responses for IFNc [1.2 pg/mL (0.7–5.1 pg/
mL) vs. 4.2 pg/mL (2.4–51.0 pg/mL); p= 0.01] and for MCP-1
[4,433.3 pg/mL (33.8–6,774.8 pg/mL) vs. 12,013.8 pg/mL
(2,197.0–23316.1 pg/mL); p= 0.018]. Both IL-1a (8.2 pg/mL
(1.8–20.3 pg/mL) vs. 16.5 pg/mL (6.6–158.0 pg/mL); p= 0.17)
and TNFa (33.3 pg/mL (6.8–144.8 pg/mL) vs. 105.1 pg/mL
(27.1–408.1 pg/mL); p = 0.08) showed trends towards decreased
production in premutation carriers, and approached but did not
reach statistical significance. After stimulation with PHA (Figure 2
E–H), IFNc [762.0 pg/mL (122.1–4,830.0 pg/mL) vs.
2,078.2 pg/mL (386.6–3,535.0 pg/mL)] no longer showed signif-
icant differences between premutation carriers and controls,
however MCP-1 from PBLs remained decreased [12,156.9 pg/
mL (1,234.2–26,497.6 pg/mL) vs. 41,296.2 pg/mL (6,874.7–
62,065.2 pg/mL); p = 0.021] and the production of IL-1a was
decreased [84.1 pg/mL (21.7–168.1 pg/mL) vs. 282.5 pg/mL
(133.7–554.0 pg/mL); p = 0.004]. TNFa [1,657.9 pg/mL (422.4–
3,595.2 pg/mL) vs. 2,634.8 pg/mL (1,507.0–5,367.9 pg/mL)]
displayed a trend towards decreased response, however, it did
not reached statistical significance.
Decreased production of cytokines was associated with in-
creased CGG repeat length. In unstimulated monocyte cultures
from human female premutation carriers, increased CGG repeat
length was associated with decreased cytokine production for GM-
CSF (r=20.409, p = 0.03), IL-1a (r=20.360, p = 0.02), and IL-
12(p40) (r=20.409, p = 0.03,). After stimulation with LPS,
cytokines such as IL-1b (p = 0.06), IL-12(p40) (p = 0.08) showed
similar trends of decreasing levels that were associated with CGG
repeat length, but failed to reach significance (Table 1). Similar
trends were present in the supernatants of the cultured PBLs. In
media alone, production of cytokines IFNc (r =20.3264,
p = 0.05), MCP-1 (r =20.289, p= 0.05), and TNFa (r =20.320,
p = 0.03) were significantly associated with CGG repeat length.
After stimulation with PHA, dynamic production of cytokines in
PBLs show significant association with production of IL-1a (r =2
0.431, p,0.01) (Table 2).
Phenotypic markers of activation were assessed on PBLs from
premutation carriers and age-matched controls by flow cytometry.
In unstimulated PBLs cultures from premutation carriers and age-
matched controls similar frequencies of CD3+CD25+ and
CD3+HLA-DR+ cells were observed; however, following stimula-
tion of PBLs with anti-CD3 and anti-CD28 antibody a significant
decrease was observed in the frequencies of CD3+CD25+ cells in
the premutation carriers (1.8% (1.67–2.78%) vs. 2.75% (1.36–
5.35%); p = 0.006). No differences in the frequency of CD3+HLA-
DR+ cells (Figure 3) were observed between cases and controls
following stimulation.
From a potential translational viewpoint, immune responses
from spleenocytes cell cultures from CGG KI mice generally
showed decreased in cytokine production, although the specific
Autoimmunity in Fragile X Premutation Carriers
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cytokines differed from those seen in PBLs from human female
premuation carriers. Specifically, after stimulation with PMA/
Ionomycin a pronounced decrease in dynamic immune response
was evident in a number of cytokines (Figure 4), including IL-6
[643.8 pg/mL (500.8–964.6 pg/mL) vs. 988.2 pg/mL (654.7–
1,185.1 pg/mL); p = 0.008], IL-13 [766.6 pg/mL (533.9–
955.3 pg/mL) vs. 1,045.3 pg/mL (606.1–1,391.9); p = 0.046],
IL-17 [420.3 pg/mL (184.1–667.9 pg/mL) vs. 680.8 pg/mL
(370.6–1,315.2 pg/mL); p = 0.022]. In addition, TNFa
(p = 0.079) and IL-10 (p = 0.141) showed trends towards decreas-
ing approaching but not reaching statitsical signfigance.
A negative association with cytokine production and CGG
repeat length seen in PBLs in human female CGG carriers was
also observed in CGG KI mice with a strong assocation between
Figure 1. Cytokine production from human monocytes. Monocytes from premutation carriers showed significant decreased production of (A)
GM-CSF and (B) IL-12(p40) but not significantly lower levels of (C) IL-1a when cultured with media alone. After LPS stimulation, dynamic production
of both (D) GM-CSF and (E) IL-1a were significantly decreased in premutation carriers, but (F) IL-12(p40) levels were levels comparable between
groups. *p,0.05.
doi:10.1371/journal.pone.0094475.g001
Figure 2. Cytokine production in human PBLs. PBLs from premutation carriers showed significantly decreased production of (A) IFNc and (B)
MCP-1; however, no apparent differences were seen in (C) IL-1a and (D) TNFa when cultured in media alone. When stimulated with a PHA, decreased
production of (E) IFNc in premutation carriers was seen and difference in (F) MCP-1 remained. Both (G) IL-1a and (H) TNFa showed trends towards
decreased production, but did not reach significance. *p,0.05, and **p,0.01.
doi:10.1371/journal.pone.0094475.g002
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production of IL-6 and CGG repeat length (r=20.330,
p = 0.008).
Discussion
Increased frequencies of autoimmune and autoinflammatory
disorders have been previously reported in female premutation
carriers, including a significant increased risk for developing
autoimmune thyroid disorders and Fibromyalgia [15,17]. How-
ever, little is known about the immune function of premutation
carriers at a cellular level. Given the increased risk of developing
autoimmune diseases and other immune related conditions,
understanding the immune function of premutation carriers
before onset of pathology could provide useful information both
in understanding the pathophysiology associated with the pre-
mutation allele as well as to the field of autoimmunity in general.
In this study we found both human and murine premutation
carriers showed impaired cellular immune responses, and that
human premutation carriers showed decreased relative levels of T
cells expressing the cell surface marker CD25+, the interleukin-2
receptor alpha chain which is upregulated on T cells during
cellular activation.
Autoimmune diseases are a very diverse set of disorders, each
with unique pathology and associated risk factors. Both genetic
studies and animal models have provided some clues as to shared
factors that contribute to increased risk of developing autoimmune
disorders. One theory that has arisen from this research is that a
deficient rather than over active immune system may be linked to
increased susceptibility for autoimmunity [28,29]. Although not
fully understood, it is believed that immunologic defects result in
lack of clearance of potential pathogens, which in turn could lead
to aberrant ongoing or chronic immune responses that eventually
contribute to the breakdown of self-tolerance. This is evident both
in some human autoimmune diseases as well as animal models of
autoimmunity. In systemic lupus erythematosus (SLE), for
example, individuals with deficiency in complement proteins such
a C1q and C4 are associated with increased risk of developing the
disorder [30]. In addition, deficiencies in antibodies, immune
regulatory proteins, and cytotoxic molecules are all associated with
increased risk of developing a number of systemic autoimmune
Table 1. CGG Repeat length vs. Cytokine production from human monocytes.
Media LPS
Cytokine P r P r
GM-CSF 0.03 20.409 0.92 0.015
IL-1a 0.02 20.360 0.27 20.176
IL-1b 0.07 20.274 0.06 20.361
IL-6 0.68 20.074 0.84 20.049
IL-10 0.09 20.261 0.98 0.005
IL-12(p40) 0.03 20.409 0.08 20.300
MCP-1 0.69 0.076 0.49 0.130
TNFa 0.06 20.289 0.17 20.227
Cytokine production from human monocytes were associated with CGG repeat length. Increased length of CGG showed a significantly (p,0.05) negative association
with IL-1a and IL-12(p40). All p-values and spearman rho-values (r) were calculated by spearman test.
doi:10.1371/journal.pone.0094475.t001
Table 2. CGG Repeat length vs. Cytokine production from human PBLs.
Media PHA
Cytokine P r P r
GM-CSF 0.09 20.260 0.53 20.09
IFNc 0.05 20.326 0.33 20.14
IL-1a 0.15 20.238 0.00 20.43
IL-1b 0.10 20.245 0.28 20.16
IL-6 0.14 20.233 0.26 20.17
IL10 0.16 20.211 0.73 20.05
IL-12(p40) 0.95 20.010 0.50 20.11
IL-13 0.56 0.111 0.59 0.08
IL-17a 0.65 20.089 0.97 20.01
MCP-1 0.05 20.288 0.15 20.21
TNFa 0.03 20.320 0.08 20.26
Cytokine production from human PBLs cultured in media alone were associated with CGG repeat length, with IFNc, MCP-1, and TNFa all showing significantly (p,0.05)
negative associations. After stimulation with PHA, however, significance with those association was diminished while a strong association (p,0.01) with IL-1a became
apparent. All p-values and spearman rho-values (r) were calculated by spearman test.
doi:10.1371/journal.pone.0094475.t002
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disorders in both human and animals models [31]. This
paradoxical association of immune deficiency and autoimmunity
appears to fall on a spectrum, ranging from subclinical infection to
severe infection and immunocompromise [32]. The decreased
cytokine production seen in this study in both human and murine
carriers of premutation alleles, as well as the previously described
increase in autoimmune conditions in female premutation carriers,
is consistent with the underlying theory that deficient responses
may predispose for autoinflammatory conditions. This idea is
further supported to some degree by anecdotal observations from
our clinics which suggest that infections, stress or major surgery
often pre-dates symptoms of autoimmunity in female premutation
carriers (R. Hagerman personal communication).
Although our previous work had found that immune mediated
disorders were only increased in female carriers, this could be for
the simple reason that these disorders are much more common in
females generally; meaning we lacked the power to determine the
impact the premutation allele has on immune disorder develop-
ment in male carriers. As male premutation carriers are less
common than females, they present inherent difficulties in
studying. However, to address the question of immune differences
between male and females premutation carries, we looked at both
males and female CGG repeat knock-in mice. Both genders
showed similar immune impairments compared with controls
(data not shown). This would suggest that human male carriers
would also show immune impairments; while these impairment do
not appear to manifest in immune related disorders, male do more
Figure 3. Cellular activation phenotype of PBLs. Frequencies of (A) CD3+CD25+ cells were significantly decreased in premutation carriers
compared to age-matched controls after twenty-four out culture with anti-CD3 (OKT3) and anti-CD28. No differences were apparent in (B) CD3+HLA-
DR+ cells between groups. *p,0.05, and p,0.01.
doi:10.1371/journal.pone.0094475.g003
Figure 4. Cytokine production in mouse splenocytes. Splenocytes from CGG KI mice display significantly decreased production of (A) IL-6, (B)
IL-13, and (C) IL-17 in responses to PMA/Ionomycin. There was a trend for decreased production of (D) TNFa, and (E) IL-10. *p,0.05, and **p,0.01.
doi:10.1371/journal.pone.0094475.g004
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commonly present with FXTAS. Recently, it was shown that
males with FXTAS had inflammatory profiles similar to what is
seen in many autoinflammatory disorders that are associated with
female premutation carriers [18]. Although male premutation
carriers do not present with the same immune disorders as female
carriers it is probable that they still show similar cellular immune
impairments.
In adult human female premutation carriers we saw decreased
immune responses which were negatively associated with CGG
repeat length. In monocytes isolated from premutation carriers,
the most pronounced differences when compared with healthy
controls were seen in production of IL-12(p40). Active IL-12 exists
as a heterodimeric cytokine of 70 kDa comprising of covalently
linked p40 and p35 subunit. The p40 subunit is constitutively
expressed and upregulated upon activation. IL-12 drives the
production of TH1 cytokines such as IFNc, and is important in the
immune response against viruses and intracellular bacteria.
Increased levels are associated with worsening of symptoms in
TH1 mediated autoimmune disorders such as multiple sclerosis
[33]. In TH2 or antibody mediated disorders, such as SLE, lower
levels of IL-12 have been seen in early onset SLE patients [34].
Furthermore, when IL-12 is administered to PBMCs from subjects
with SLE in vitro it leads to decreased autoantibody production
[35]. In some lupus susceptible strains of mice, IL-12 production is
reduced as well [36]. Thus, potentially, the reduction in IL-12
production could explain the pattern of immune diseases seen in
premutation carriers, who do not show significantly increased rates
of TH1 mediated autoimmunity, but rather increases in antibody
mediated disorders such as thyroid autoimmune disorders [17].
IL-12(p40) levels were unfortunately below the detection level in
the CGG KI mouse splenocytes cultures (data not shown).
Experiments looking at purified monocytes or bone-marrow
derived macrophages in these animals may further elucidate the
role of IL-12 in this model.
The decrease of IL-12(p40) production in the monocytes of
human female premutation carriers, might contribute to the
differences in the production of IFNc observed in the PBLs, as IL-
12 skews T-cells to a TH1 phenotype, which in turn produce IFNc.
In the CGG KI mice, IFNc production was decreased
[13,045.9 pg/mL (8,165.8–18,673.3 pg/mL) vs. 14,035.9 pg/mL
(9,586.0–21,879.0)], but failed to reach significance. A lack of
statistical difference may relate to the age of the mice used in these
experiments. Six month old mice were chosen to better model the
mean age of the human subjects (48 years of age at time of draw).
However, the IFNc production of these ‘‘aged’’ mice varied
greatly in both CGG KI and control WT littermates. Differences
may have been more apparent in younger animals. However,
statistical differences were seen in the CGG KI-mice for the
decreased production of inflammatory cytokines including IL-6
and IL-17. This may relate to altered T-cell function, or belie a
more generalized impairment in cytokine production related to
cellular function.
In PBLs of human female premutation carriers decreased
production of monocyte chemoattractant protein-1 (MCP-1/
CCL2) was observed with and without stimulation. MCP-1 is a
chemokine that plays a major role in selectively recruiting
monocytes and lymphocytes to sites of infection. It is vital for
proper immune surveillance, and clearance of invading pathogens
[37]. MCP-1 has both proinflammatory and anti-inflammatory
roles depending on the environmental context. The proinflamma-
tory role is in the recruitment of antigen presenting cells (APCs)
and T-cells to the site of infection, the anti-inflammatory affects
are dependent on the recruitment of regulatory T cells. The
decreased response may indicate an inability to recruit cells at sites
of infection and there after a decreased ability to clear potentially
harmful pathogens from the body.
PBL’s from human female premutation carriers also had
significantly decreased CD3+CD25+ cells, while the number of
CD3+HLA-DR+ cells was not different (Figure 3). This suggests
potential differences in the activation of T-cells. CD25 is a marker
of cellular activation, but within the CD25 expressing cells are a
population of regulatory T cells that regulate the immune system.
Further analysis on FoxP3 expression as well as functional assays
to determine the differences in T effector or regulatory T cells are
needed to determine if this data reflects a decrease in the ability to
induce a certain type of adaptive regulatory T-cell. However,
although hypothetical at this stage, deficiencies in regulatory T-
cells could contribute to the increased rate of immune disorders
seen in female premutation carriers.
CGG repeat length was significantly associated with decreased
cytokine production in both humans and mice. In female
premutation carriers, the association with CGG length and
decreased cytokine production in unstimulated monocyte cultures
was evident for inflammatory cytokines such a GM-CSF and IL-
12(p40), and IFNc and IL-1a. These cytokines were also
negatively associated with CGG length in unstimulated and
PHA stimulated PBL cultures respectively. In mice, IL-6 levels
were found to negatively associate with CGG repeat length as well.
The relationship with CGG repeat length and immune function
may be more complicated. Mice with mid-length repeats closer to
70 CGG repeats in length appeared to be more immunologically
impaired than the high-repeat length animals with repeats nearer
to 150 CGG repeats, suggesting the relationship may be non-
linear. This complex relationship to CGG repeat length has also
been observed in human premutation carries where mid length
CGG repeat size appears to have the highest rate of FXPOI [7]
and psychiatric problems including depression [13,38]. Further
research is warranted to elucidate the mechanism by which
increased CGG repeats contribute to immune dysregulation and
the development of autoinflammatory conditions. This association
between CGG repeats and immune dysfunction may have
important implications for those in the general population as well.
As the premutation is highly prevalent in society, nearing 1% of
the female population, routine screening for CGG repeat length in
the clinic may be a useful predictive tool for individuals that
present with autoinflammatory conditions, although more re-
search is warranted. In addition, targeting dysfunction based on
repeat CGG’s could lead to novel therapies.
Conclusion
In this study we report a significantly altered dynamic cytokine
profile in both in human and mouse premutation carriers before
development of symptomatology. The characterization of an
immunological profile in CGG repeat carriers without disease may
help to elucidate if an abnormal immune response may play a role
in the premutation phenotype, as well as further identifying risk
factors of autoimmunity in the general population, as nearly 1 in
130 women carry the premutation allele.
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